Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
Active, enrolledPhase 2Results postedLast updated 18 September 2025
What this trial tests
Phase 2 trial testing Conventional Surgery in Ann Arbor Stage I Childhood Hodgkin Lymphoma in 188 participants. Participants enrolled and being followed up; not accepting new ones.
Adults 1 Month to 21, any sex, with Ann Arbor Stage I Childhood Hodgkin Lymphoma or Ann Arbor Stage II Childhood Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Failure-free Survival (FFS)Primary· At 5 years
The time to a treatment (strategy) failure, where failure includes one of the following occurrences as a first event: disseminated disease (\> Stage I/II) progression or recurrence at any time, local disease progression or recurrence anytime during or after treatment with AV-PC +/- IFRT, occurrence of a second malignant neoplasm, death from any cause.
Group
Value
95% CI
Surgery or Combination Chemotherapy, With/Without Radiotherapy
0.91
0.86 – 0.95
Event-free SurvivalSecondary· At 5 years
Failure includes one of the following occurrences as a first event: relapse/progression or second malignancy from enrollment.
Group
Value
95% CI
Surgery or Combination Chemotherapy, With/Without Radiotherapy
0.85
0.78 – 0.89
Cure by Surgery Alone in Stage I Resected PatientsSecondary· At 2 years
To estimate the proportion of Stage I patients (with a single involved lymph node that is totally resected) who can be cured with surgery alone.
Group
Value
95% CI
Surgery or Combination Chemotherapy, With/Without Radiotherapy
0.82
0.68 – 0.90
Cure by AV-PC x 3 or AV-PC x 3 + IFRT for Stage I Unresected, Stage I Resected Whose Disease Recurred, and Stage II PatientsSecondary· At 5 years
To estimate the proportions of Stage I unresected, Stage I resected (whose disease has recurred after observation), and Stage II LPHD patients who can be cured with AV-PC x 3, with IFRT for those who are not in a CR after chemotherapy.
Group
Value
95% CI
Surgery or Combination Chemotherapy, With/Without Radiotherapy
0.89
0.82 – 0.93
Grade 3 or 4 ToxicitySecondary· Any time during chemoradiotherapy, up to the end of 3-cycles of AV-PC induction. Each cycle is 21 days.
Group
Value
95% CI
Surgery or Combination Chemotherapy, With/Without Radiotherapy
26
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Surgery or Combination Chemotherapy, With/Without Radiotherapy
This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04729959 — Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Gliob
· Phase 2
· active not recruiting
NCT04221438 — Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
· Phase 2
· terminated
NCT04675710 — Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
· Phase 2
· active not recruiting
NCT05252260 — Comparison of Diode Laser-Assisted Vestibuloplasty And Conventional Vestibuloplasty
· NA
· completed
NCT03808779 — A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.
· NA
· unknown
Other Children's Oncology Group trials
Trials by the same sponsor.
NCT07412002 — Quality of End-of-Life Care for Children With Cancer
· not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant
· Phase 1
· withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
· Phase 3
· not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk
· Phase 2, PHASE3
· not yet recruiting
NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00107198.